Activated Blood Protease Factor Development

As a specialized CDMO, we operate within a staged framework that cascades from Pharmaceutical Development & Manufacturing → Drug Substance Development → Blood Factor Development. Within this structure, we focus on activated blood protease factors, translating concepts into robust, phase-appropriate drug-substance processes and analytics.

Controlled Proteolytic Activation Service

We design activation schemes that convert zymogens to active proteases with tight temporal and stoichiometric control. Parameters such as ionic strength, cofactors, phospholipid or membrane mimetics, and temperature are tuned to maximize yield of the target active species while suppressing over-activation cascades. In addition, we define stop conditions, quench strategies, and inhibitor holds to freeze the catalytic state for immediate downstream capture.

Purification & Active-State Stabilization Service

Active proteases are purified with orthogonal selectivity—ion-exchange, affinity, and fine-tuned size-exclusion—sequenced to minimize contact time under catalytically permissive conditions. We incorporate inhibitor-guarded handling, low-shear fluidics, and contact-time limits to constrain autolysis. Stabilization strategies include pH/ionic balance, reversible active-site occupancy during processing, and removal of pro-autolytic fragments.

Potency & Mechanism Bioassay Development Service

We build potency methods that read out true catalytic function. Options include chromogenic or fluorogenic peptide substrates, cofactor-reconstituted complex assays (e.g., prothrombinase-like panels), and kinetic profiling across defined substrate ranges. Identity and mechanism are cross-verified with active-site titration, inhibition patterns, and peptide-mapping fingerprints. Phase-appropriate qualification ensures method ruggedness for technology packages.

Impurity Profiling & Proteolysis Mapping Service

Beyond standard host-cell impurity testing, we characterize proteolytic micro-heterogeneity: clipped species, neo-N/C termini, and autoproteolysis ladders. High-resolution mass spectrometry, intact mass with deconvolution, and peptide-map overlays are combined with SDS-PAGE/CE-SDS and activity-slice analytics. We link impurity profiles to potency and stability, establishing control strategies and acceptance boundaries for development lots.

Scale-Aware Process and Analytical Technology (AT) Package Service

Although our emphasis is the R&D stage, we assemble scale-aware documentation: unit-operation descriptions, critical process parameters, in-process controls, and linked analytical methods. We define robustness windows, material attributes (e.g., zymogen quality), and risk-based control strategies that de-risk the transition to manufacturing without duplicating production or technology-transfer activities.